Studies on the Eficacy of Intramuscular Risperidone Microspheres and Oral Risperidone in the Treatment of Schizophrenia
Objective To investigate the efficacy of intramuscular risperidone microspheres and oral risperidone in the treatment of schizophrenia, and to provide the basis for clinical drug of choice. Methods 80 cases of patients with schizophrenia were randomly divided into intramuscular risperidone microspheres(RLAI) group and the oral risperidone piece group, 12 weeks of treatment. Evaluate the efficacy and adverse reactions in the treatment of 1, 4, 8 and 12 weeks using the Positive and Negative Syndrome Scale(PANSS), the Clinical Global Impression(CGI-SI), adverse reactions Scale(TESS). Results The PANSS total score and CGI-SI score in both groups was significantly decreased(P<0.01) than before treatment. Compared with baseline, there are significant differences in the PANSS score after 4 weeks. Treatment efficiency in two group is very close to. The adverse drug reactions of RLAI group was significantly lower than the oral risperidone group(P<0.05). Conclusion The efficacy of intramuscular risperidone microspheres and oral risperidone tablets in the treatment of schizophrenia is very close to, The RLAI group adverse reactions are less and lighter than oral risperidone. Intramuscular risperidone microspheres for treatment of schizophrenia is safe and effective, and Patient treatment compliance is better than oral risperidone.
NETL
NSTL
万方数据
维普
